The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Salvage locoregional therapies for recurrent hepatocellular carcinoma
World J Gastroenterol. 2023 Jan 21;29(3):413-424. doi: 10.3748/wjg.v29.i3.413.
1Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio 45701, United States.
2Department of Radiology, The Ohio State University Wexner Medical Center, Columbus, Ohio 43210, United States. mina.makary@osumc.edu.
Abstract
Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death worldwide. Despite the advent of screening efforts and algorithms to stratify patients into appropriate treatment strategies, recurrence rates remain high. In contrast to first-line treatment for HCC, which relies on several factors, including clinical staging, tumor burden, and liver function, there is no consensus or general treatment recommendations for recurrent HCC (R-HCC). Locoregional therapies include a spectrum of minimally invasive liver-directed treatments which can be used as either curative or neoadjuvant therapy for HCC. Herein, we provide a comprehensive review of recent evidence using salvage loco-regional therapies for R-HCC after failed curative-intent.